Management of Carbapenemase-Producing Enterobacteriaceae in Intensive Care Unit

Infections due to carbapenemase-producing enterobacteriaceae may represent a potential threat due to the scarcity of the available therapeutic resources. OXA-48 and OXA-48-like are most prevalent in France. Older agents have become the last resort choices as treatment options are relatively few and combination therapy with optimal administration should be considered. Therapeutic future options as well as randomized controlled trials are needed. Meanwhile, we need to look at experiences of those managing this health problem and promoting better use of antibiotics stands as a sheer necessity.